Chronic kidney disease affects an estimated 10 to 16 percent of the global population, and that number is rising. For most patients, the standard treatment path — managing blood pressure, controlling blood sugar, reducing protein in the diet — slows the progression of the disease but does not stop it. Once kidney function deteriorates past a certain point, dialysis or transplantation become the only remaining options.

That gap between management and repair is exactly what researchers are trying to close with stem cell therapy. Over the past decade, umbilical cord-derived mesenchymal stem cells — UC-MSCs — have emerged as one of the most studied biological approaches to kidney disease, and the clinical evidence is beginning to take shape.

This article covers what the current research actually shows: how UC-MSCs work in the context of kidney disease, what clinical trials have found, what measurable improvements patients have experienced, and what side effects the evidence documents.

Why the Kidneys Are Difficult to Treat

The kidney’s core challenge is structural. When kidney tissue is damaged — whether by diabetes, high blood pressure, autoimmune disease, or chronic inflammation — the body’s natural repair response tends to produce fibrosis rather than healthy tissue. Scar tissue replaces functioning nephrons, filtration capacity drops, and the process becomes self-reinforcing. Standard medications can slow the rate at which this happens, but nothing currently approved can meaningfully reverse it.

This is why stem cell therapy has attracted serious clinical attention. The premise is not that stem cells directly become new kidney tissue. The mechanism is more precise than that — and more relevant to how CKD actually progresses.

How UC-MSCs Work in Kidney Disease

UC-MSCs do not repair the kidney by transforming into new kidney cells. Their primary effect is immunomodulatory and anti-inflammatory — they change the environment the kidney is operating in, rather than replacing what has been lost.

In the context of kidney disease, this matters because chronic inflammation and immune dysregulation are major drivers of disease progression. UC-MSCs act through several overlapping pathways: they reduce inflammatory cytokines, suppress the immune cells responsible for ongoing tissue attack, promote the growth of new blood vessels to improve perfusion, and slow the fibrosis process that progressively reduces functional kidney tissue.

The result, when it works, is not a reversal of existing damage but a stabilisation and in some cases partial improvement of kidney function — measured primarily through eGFR (estimated glomerular filtration rate), serum creatinine, and urinary protein levels.

What Clinical Trials Have Found

Clinical evidence since 2020 has focused primarily on diabetic nephropathy and CKD stages 3 and 4. Key findings:

A 2023 randomised trial showed MSC therapy notably reduced eGFR deterioration over 18 months in diabetic kidney disease patients. An 8-year follow-up RCT found UC-MSC treatment reduced chronic complications including diabetic nephropathy in type 1 diabetes patients.

A 2025 BMC Nephrology review of a decade of CKD trials found MSC infusion consistently improved glomerular filtration rate, urine protein, serum creatinine, and blood urea nitrogen, while increasing regulatory T cells.

The pattern is consistent: UC-MSC therapy slows functional decline and improves measurable kidney markers at standard doses.

Side Effects: What the Research Documents

This is an area where the published evidence is both reassuring and worth understanding clearly.

Across all clinical studies reviewed in the 2025 BMC Nephrology analysis, no serious adverse events were found to be directly attributable to MSC infusion in CKD patients. The adverse events that did occur — and some did — were transient and mild.

Documented post-infusion symptoms include: transient fever, fatigue, nausea, headache, dizziness, mild body aches, flushing, and in some cases insomnia or constipation in the days following treatment. Upper respiratory tract infections were the most commonly reported adverse event across studies, though researchers consistently noted these appeared independent of the infusion itself rather than caused by it.

The symptoms most patients experience — tiredness, mild nausea, and body aches — are consistent with a short-term immune response as the body processes the infusion. They typically resolve within 24 to 72 hours without intervention.

When to Seek Immediate Medical Attention

Most post-infusion symptoms are mild and resolve on their own. The following are different — they require contacting your medical team immediately, not waiting to see if they pass.

In the first 3 to 6 hours after infusion, watch for:

• Chest pain or tightness, heart palpitations, or sudden dizziness and cold sweats — these are cardiovascular warning signs that need same-day assessment.
• Difficulty breathing, shortness of breath, or persistent wheezing.
• Skin rash, hives, sudden facial or throat swelling, or any sensation of throat tightening — these are signs of an allergic reaction that require urgent attention.

In the days following infusion:

• Fever above 38.5°C that does not come down with rest and hydration.
• A sudden and significant drop in urine output, or rapid swelling in the legs and ankles.
• Redness, warmth, or increasing pain at the infusion site.
• Any new neurological symptoms — sudden severe headache, confusion, or numbness that does not resolve.

The distinction that matters is direction: symptoms that are mild and fading are a normal immune response. Symptoms that are new, intensifying, or appearing several hours after the initial post-infusion window should always be reported to your clinical team without delay.

Who Is Currently Being Studied

The patient populations showing the most consistent results in current trials are those with diabetic nephropathy and hypertensive kidney disease at CKD stages 3 and 4 — where kidney function is meaningfully reduced but not yet at end-stage. This is the window where slowing or partially reversing functional decline has the most clinical impact.

Patients with active infection, active cancer, or multi-organ failure are consistently excluded from trials, and these remain contraindications in clinical practice.

Where the Research Is Heading

Several randomised, double-blind, placebo-controlled trials of UC-MSC therapy for CKD stages 3 and 4 are currently recruiting or underway, with completion dates ranging from 2025 to 2027. These trials are designed to produce the kind of high-quality evidence that moves a therapy from promising to standard of care.

The questions researchers are now focused on are not whether UC-MSC therapy is safe — that has been consistently established. The open questions are about optimising dose, timing, frequency of infusion, and which patient profiles respond best.

The Honest Summary

UC-MSC therapy for kidney disease is not a cure and does not reverse established damage. What the current evidence supports is this: at appropriate doses, administered in a properly controlled clinical setting, UC-MSC IV infusion consistently slows the progression of kidney disease, improves measurable kidney function markers, and does so with a well-documented and manageable side effect profile.

The side effects patients commonly experience — fatigue, mild nausea, body aches, and low-grade fever — are transient immune responses that resolve on their own. Serious adverse events directly attributable to UC-MSC infusion have not been established in CKD-specific trials conducted under proper clinical protocols.

For patients who have exhausted conventional management options and are looking for something that addresses the underlying disease process rather than just its symptoms, the research is increasingly pointing in a meaningful direction.

About EDNA Wellness

EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).

All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.

For more information or to book a consultation:

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

www.ednawellness.com

References

• Lv, S., et al. (2025). Immunomodulatory effects of mesenchymal stem cell therapy in chronic kidney disease: a literature review. BMC Nephrology, 26, 104. https://pmc.ncbi.nlm.nih.gov/articles/PMC11874639/
• Wang, Y., et al. (2024). Narrative review of mesenchymal stem cell therapy in renal diseases: mechanisms, clinical applications, and future directions. Stem Cells International. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655143/
• Hu, J., et al. (2022). Results from an 8-year follow-up randomized controlled trial of UC-MSC treatment in type 1 diabetes with diabetic nephropathy. ClinicalTrials.gov NCT01374854.
• Kim, B.S., et al. (2017). Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy. Kidney International Reports. https://pubmed.ncbi.nlm.nih.gov/28680828/